secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-117573
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023
--------------------------------------------------------------------------------

- Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.
- Operating loss $1.7M, improved 53% YoY; net loss $1.9M vs $4.2M in Q3 2022.
- 2023 guidance reaffirmed: net sales $82-86M (+17-18% YoY), gross profit $8-10M (+95-144% YoY).
- Company now expects adjusted EBITDA profitability in Q4 2023, ahead of prior 2024 target.
- Acquired Evoqua hemodialysis concentrates assets; became leading US supplier of liquid bicarbonate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/0001104659-23-117573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/tm2330647d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer